logo
Share SHARE
FONT-SIZE Plus   Neg

Genmab Announces First Phase III Trial Of Daratumumab - Quick Facts

Denmark-based biotechnology company Genmab A/S (GNMSF.PK) said its partner, Janssen Biotech, Inc. would begin a Phase III study of daratumumab in relapsed or refractory multiple myeloma. The trial would compare daratumumab in combination with lenalidomide and dexamethasone to lenalidomide and dexamethasone alone.

Genmab's Chief Executive stated: "The daratumumab development program is progressing very well. We are extremely pleased to be able to announce that this study evaluating daratumumab in combination with a core multiple myeloma treatment regime will initiate patient recruitment in the coming months."

The Phase III trial would comprise nearly 500 patients with relapsed or refractory multiple myeloma. Patients would be randomized to receive either daratumumab combined with lenalidomide and dexamethasone, or lenalidomide and dexamethasone alone. The company said the study's primary endpoint is progression free survival.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Los Angeles City officials have filed criminal charges against Soylent CEO Robert Rhinehart for placing a bright red shipping container on Montecito Heights hillside as part of his "experiment in sustainable living." City Attorney Mike Feuer Friday announced that his office has filed multiple criminal... A new study says that if Hillary Clinton is elected then her proposals will strengthen the U.S. economy and create millions of jobs. According to Moody's Analytics, Hillary Clinton's economic proposal would oversee a "somewhat stronger U.S. economy." The conclusion was reached after assessing her... Oil company Exxon Mobil Corp. on Friday reported a 59 percent fall in profit for the second quarter from last year, while Chevron Corp. reported a loss for the quarter, both on lower revenues. The results of both companies were impacted by the low crude oil and natural gas prices as well as weaker refining margins.
comments powered by Disqus
Follow RTT